• Please log in or register to access this feature.

Original Article

You have full text access to this OnlineOpen article

The effect of menatetrenone, a vitamin K2 analog, on disease recurrence and survival in patients with hepatocellular carcinoma after curative treatment

A pilot study

  1. Toshihiko Mizuta M.D.1,†,*,
  2. Iwata Ozaki M.D.1,2,
  3. Yuichiro Eguchi M.D.1,
  4. Tsutomu Yasutake M.D.1,
  5. Seiji Kawazoe M.D.1,
  6. Kazuma Fujimoto M.D.1,
  7. Kyosuke Yamamoto M.D.1

Article first published online: 6 JAN 2006

DOI: 10.1002/cncr.21667

Issue

Cancer

Cancer

Volume 106, Issue 4, pages 867–872, 15 February 2006

Additional Information

How to Cite

Mizuta, T., Ozaki, I., Eguchi, Y., Yasutake, T., Kawazoe, S., Fujimoto, K. and Yamamoto, K. (2006), The effect of menatetrenone, a vitamin K2 analog, on disease recurrence and survival in patients with hepatocellular carcinoma after curative treatment. Cancer, 106: 867–872. doi: 10.1002/cncr.21667

Author Information

  1. 1

    Department of Internal Medicine, Saga Medical School, Saga, Japan

  2. 2

    Health Administration Center, Saga Medical School, Saga, Japan

  1. †

    Fax: 011 (81) 952342017

*Department of Internal Medicine, Saga Medical School, 5-1-1 Nabeshima, Saga 849-8501, Japan

  1. †

    Fax: 011 (81) 952342017

Publication History

  1. Issue published online: 3 FEB 2006
  2. Article first published online: 6 JAN 2006
  3. Manuscript Received: 9 NOV 2005
  4. Manuscript Accepted: 12 SEP 2005
  5. Manuscript Revised: 27 AUG 2005

Funded by

  • Intractable Hepatitis Study Group of Japan

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (134K)

REFERENCES

  • 1
    Sherlock S, Dooley J. Malignant liver tumors. In: SherlockS, DooleyJ, editors. Disease of the liver and biliary system. Oxford: Blackwell Science, 2002: 537–561.
  • 2
    The Liver Cancer Study Group of Japan. Predictive factors for long-term prognosis after partial hepatectomy for patients with hepatocellular carcinoma in Japan. Cancer. 1994; 74: 2772–2780.
    Direct Link:
  • 3
    Furie B, Bouchard BA, Furie BC. Vitamin K-dependent biosynthesis of γ-carboxyglutamic acid. Blood. 1999; 93: 1798–1808.
  • 4
    Shearer MJ. The roles of vitamin D and vitamin K in bone health and osteoporosis prevention. Proc Nutr Soc. 1997; 56: 915–937.
  • 5
    Chlebowski RT, Dietrich M, Akman S, Block JB. Vitamin K3 inhibition of malignant murine cell growth and human tumor colony formation. Cancer Treat Rep. 1985; 69: 527–532.
  • 6
    Nishikawa Y, Carr BI, Wang M, et al. Growth inhibition of hepatoma cells induced by vitamin K and its analogs. J Biol Chem. 1995; 270: 28304–28310.
  • 7
    Sakai I, Hashimoto S, Yoda M, et al. Novel role of vitamin K2: a potent inducer of differentiation of various human myeloid leukemia cell lines. Biochem Biophys Res Commun. 1994; 205: 1305–1310.
  • 8
    Wu FYH, Liao WC, Chang HM. Comparison of antitumor activity of vitamins K1, K2, K3 on human tumor cells by two (MTT and SRB) cell viability assays. Life Sci. 1993; 52: 1797–1804.
  • 9
    Wang Z, Wang M, Finn F, Carr BI. The growth inhibitory effects of vitamins K and their actions on gene expression. Hepatology. 1995; 22: 876–882.
  • 10
    Takami A, Nakao S, Ontachi Y, Yamauchi H, Matsuda T. Successful therapy of myelodysplastic syndrome with menatetrenone, a vitamin K2 analog. Int J Hematol. 1999; 69: 24–26.
  • 11
    Liebman HA, Furie BC, Tong M, et al. Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. N Engl J Med. 1984; 310: 1427–1431.
  • 12
    Nakagawa T, Seki T, Shiro T, et al. Clinicopathologic significance of protein induced vitamin K absence or antagonist II and alpha-fetoprotein in hepatocellular carcinoma. Int J Oncol. 1999; 14: 281–286.
  • 13
    Koike Y, Shiratori Y, Sato S, et al. Des-γ-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma. A prospective analysis of 227 patients. Cancer. 2001; 91: 561–569.
    Direct Link:
  • 14
    Furukawa M, Nakanishi T, Okuda H, Ishida S, Obata H. Changes of plasma des-γ-carboxy-prothrombin levels in patients with hepatocellular carcinoma in response to vitamin K. Cancer. 1992; 69: 31–38.
    Direct Link:
  • 15
    Orimo H, Shiraki M, Tomita A, Morii H, Fujita T, Ohata M. Effects of menatetrenone on the bone and calcium metabolism in osteoporosis: a double-blind placebo-controlled study. J Bone Miner Metab. 1998; 16: 106–112.
  • 16
    Bruix J, Sherman M, Llvet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001; 35: 421–430.
  • 17
    Bouzahazah B, Nishikawa Y, Simon D, Carr BI. Growth control and gene expression in a new hepatocellular carcinoma cell line, Hep40: inhibitory actions of vitamin K. J Cell Physiol. 1995; 165: 459–467.
    Direct Link:
  • 18
    Ohizumi H, Masuda Y, Nakajo S, Sakai I, Ohsawa S, Nakaya K. Geranylgeraniol is a potent inducer of apoptosis in tumor cells. J Biochem. 1995; 117: 11–13.
  • 18
    Yoshida H, Shiratori Y, Moriyama M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. Ann Intern Med. 1999; 131: 174–181.
  • 20
    Kubo S, Nishiguchi S, Hirohashi K, et al. Effects of long-term postoperative interferon-α therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. Ann Intern Med. 2001; 134: 963–967.
  • 21
    Muto Y, Moriwaki H, Ninomiya M, et al. The Hepatoma Prevention Study Group. Prevention of second primary tumor by an acyclic retinoid, polyrenoic acid, in patients with hepatocellular carcinoma. N Engl J Med. 1996; 334: 1561–1567.
View Full Article (HTML) Get PDF (134K)